HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

BACKGROUND: Targeted therapies have improved therapeutic options of treating renal cell carcinoma (RCC). However, drug response is temporary due to resistance development. METHODS: Functional and molecular changes in RCC Caki-1 cells, after acquired resistance to the mammalian target of rapamycin (m...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Juengel, Eva, Nowaz, Snigdha, Makarevi, Jasmina, Natsheh, Iyad, Werner, Isabella, Nelson, Karen, Reiter, Michael, Tsaur, Igor, Mani, Jens, Harder, Sebastian, Bartsch, Georg, Haferkamp, Axel, Blaheta, Roman A
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2014
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4073177/
https://ncbi.nlm.nih.gov/pubmed/24935000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-152
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires